The role of vitamin D in type 2 diabetes and hypertension

Vitamin D

Volumn , Issue , 2011, Pages 1907-1930

  Pittas, Anastassios G ^a   Dawson Hughes, Bess ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84879556117     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-381978-9.10098-8     Document Type: Chapter

References (190)

1. Narayan K.M., Boyle J.P., Geiss L.S., Saaddine J.B., Thompson T.J. Impact of recent increase in incidence on future diabetes burden: U.S., 2005-2050. Diabetes Care 2006, 29:2114-2116.
2. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
3. Hogan P., Dall T., Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care 2003, 26:917-932.
4. Ezzati M., Lopez A.D., Rodgers A., Vander Hoorn S., Murray C.J. Selected major risk factors and global and regional burden of disease. Lancet 2002, 360:1347-1360.
5. Kaplan N.M., Opie L.H. Controversies in hypertension. Lancet 2006, 367:168-176.
6. Kearney P.M., Whelton M., Reynolds K., Muntner P., Whelton P.K., He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365:217-223.
7. Kabakov E., Norymberg C., Osher E., Koffler M., Tordjman K., Greenman Y., et al. Prevalence of hypertension in type 2 diabetes mellitus: impact of the tightening definition of high blood pressure and association with confounding risk factors. J. Cardiometab. Syndr. 2006, 1:95-101.
8. Hu F.B., Manson J.E., Stampfer M.J., Colditz G., Liu S., Solomon C.G., et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N. Engl. J. Med. 2001, 345:790-797.
9. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 2002, 346:393-403.
10. Tuomilehto J., Lindstrom J., Eriksson J.G., Valle T.T., Hamalainen H., Ilanne-Parikka P., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 2001, 344:1343-1350.
11. Uusitupa M., Lindi V., Louheranta A., Salopuro T., Lindstrom J., Tuomilehto J. Long-term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance: 4-year results from the Finnish Diabetes Prevention Study. Diabetes 2003, 52:2532-2538.
12. Knowler W.C., Fowler S.E., Hamman R.F., Christophi C.A., Hoffman H.J., Brenneman A.T., et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009, 374:1677-1686.
13. Chobanian A.V. Shattuck Lecture. The hypertension paradox - more uncontrolled disease despite improved therapy. N. Engl. J. Med. 2009, 361:878-887.
14. Cutler J.A., Sorlie P.D., Wolz M., Thom T., Fields L.E., Roccella E.J. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008, 52:818-827.
15. Pittas A.G., Lau J., Hu F.B., Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 2007, 92:2017-2029.
16. Pittas A.G., Chung M., Trikalinos T., Mitri J., Brendel M., Patel K., et al. Systematic review: vitamin D and cardiometabolic outcomes. Ann. Intern. Med. 2010, 152:307-314.
17. Hu F.B., Meigs J.B., Li T.Y., Rifai N., Manson J.E. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 2004, 53:693-700.
18. Lillioja S., Mott D.M., Spraul M., Ferraro R., Foley J.E., Ravussin E., et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N. Engl. J. Med. 1993, 329:1988-1992.
19. Adrogue H.J., Madias N.E. Sodium and potassium in the pathogenesis of hypertension. N. Engl. J. Med. 2007, 356:1966-1978.
20. Norman A.W., Frankel J.B., Heldt A.M., Grodsky G.M. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science 1980, 209:823-825.
21. Chertow B.S., Sivitz W.I., Baranetsky N.G., Clark S.A., Waite A., Deluca H.F. Cellular mechanisms of insulin release: the effects of vitamin D deficiency and repletion on rat insulin secretion. Endocrinology 1983, 113:1511-1518.
22. Kadowaki S., Norman A.W. Dietary vitamin D is essential for normal insulin secretion from the perfused rat pancreas. J. Clin. Invest. 1984, 73:759-766.
23. Tanaka Y., Seino Y., Ishida M., Yamaoka K., Yabuuchi H., Ishida H., et al. Effect of vitamin D3 on the pancreatic secretion of insulin and somatostatin. Acta Endocrinol. (Copenh.) 1984, 105:528-533.
24. Cade C., Norman A.W. Vitamin D3 improves impaired glucose tolerance and insulin secretion in the vitamin D-deficient rat in vivo. Endocrinology 1986, 119:84-90.
25. Bourlon P.M., Faure-Dussert A., Billaudel B. The de novo synthesis of numerous proteins is decreased during vitamin D3 deficiency and is gradually restored by 1,25-dihydroxyvitamin D3 repletion in the islets of Langerhans of rats. J. Endocrinol. 1999, 162:101-109.
26. Cade C., Norman A.W. Rapid normalization/stimulation by 1,25-dihydroxyvitamin D3 of insulin secretion and glucose tolerance in the vitamin D-deficient rat. Endocrinology 1987, 120:1490-1497.
27. Clark S.A., Stumpf W.E., Sar M. Effect of 1,25 dihydroxyvitamin D3 on insulin secretion. Diabetes 1981, 30:382-386.
28. Johnson J.A., Grande J.P., Roche P.C., Kumar R. Immunohistochemical localization of the 1,25(OH)2D3 receptor and calbindin D28k in human and rat pancreas. Am. J. Physiol. 1994, 267:E356-360.
29. Zeitz U., Weber K., Soegiarto D.W., Wolf E., Balling R., Erben R.G. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J. 2003, 17:509-511.
30. Bland R., Markovic D., Hills C.E., Hughes S.V., Chan S.L., Squires P.E., et al. Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in pancreatic islets. J. Steroid Biochem. Mol. Biol. 2004, 89-90:121-125.
31. Sergeev I.N., Rhoten W.B. 1,25-Dihydroxyvitamin D3 evokes oscillations of intracellular calcium in a pancreatic beta-cell line. Endocrinology 1995, 136:2852-2861.
32. Milner R.D., Hales C.N. The role of calcium and magnesium in insulin secretion from rabbit pancreas studied in vitro. Diabetologia 1967, 3:47-49.
33. Yasuda K., Hurukawa Y., Okuyama M., Kikuchi M., Yoshinaga K. Glucose tolerance and insulin secretion in patients with parathyroid disorders. Effect of serum calcium on insulin release. N. Engl. J. Med. 1975, 292:501-504.
34. Gedik O., Zileli M.S. Effects of hypocalcemia and theophylline on glucose tolerance and insulin release in human beings. Diabetes 1977, 26:813-819.
35. Fujita T., Sakagami Y., Tomita T., Okamoto Y., Oku H. Insulin secretion after oral calcium load. Endocrinol. Jpn. 1978, 25:645-648.
36. Kadowaki S., Norman A.W. Pancreatic vitamin D-dependent calcium binding protein: biochemical properties and response to vitamin D. Arch. Biochem. Biophys. 1984, 233:228-236.
37. Sooy K., Schermerhorn T., Noda M., Surana M., Rhoten W.B., Meyer M., et al. Calbindin-D(28k) controls [Ca(2+)](i) and insulin release. Evidence obtained from calbindin-d(28k) knockout mice and beta cell lines. J. Biol. Chem. 1999, 274:34343-34349.
38. Giarratana N., Penna G., Amuchastegui S., Mariani R., Daniel K.C., Adorini L. A vitamin D analog down-regulates proinflammatory chemokine production by pancreatic islets inhibiting T cell recruitment and type 1 diabetes development. J. Immunol. 2004, 173:2280-2287.
39. Gysemans C.A., Cardozo A.K., Callewaert H., Giulietti A., Hulshagen L., Bouillon R., et al. 1,25-Dihydroxyvitamin D3 modulates expression of chemokines and cytokines in pancreatic islets: implications for prevention of diabetes in nonobese diabetic mice. Endocrinology 2005, 146:1956-1964.
40. Chiu K.C., Chu A., Go V.L., Saad M.F. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am. J. Clin. Nutr. 2004, 79:820-825.
41. Kayaniyil S., Vieth R., Retnakaran R., Knight J.A., Qi Y., Gerstein H.C., et al. Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes. Diabetes Care 2010, 33:1379-1381.
42. Gulseth H.L., Gjelstad I.M., Tierney A.C., Lovegrove J.A., Defoort C., Blaak E.E., et al. Serum vitamin D concentration does not predict insulin action or secretion in European subjects with the metabolic syndrome. Diabetes Care 2010, 33:923-925.
43. Leal M.A., Aller P., Mas A., Calle C. The effect of 1,25-dihydroxyvitamin D3 on insulin binding, insulin receptor mRNA levels, and isotype RNA pattern in U-937 human promonocytic cells. Exp. Cell Res. 1995, 217:189-194.
44. Maestro B., Campion J., Davila N., Calle C. Stimulation by 1,25-dihydroxyvitamin D3 of insulin receptor expression and insulin responsiveness for glucose transport in U-937 human promonocytic cells. Endocr. J. 2000, 47:383-391.
45. Maestro B., Molero S., Bajo S., Davila N., Calle C. Transcriptional activation of the human insulin receptor gene by 1,25-dihydroxyvitamin D(3). Cell Biochem. Funct. 2002, 20:227-232.
46. Maestro B., Davila N., Carranza M.C., Calle C. Identification of a vitamin D response element in the human insulin receptor gene promoter. J. Steroid Biochem. Mol. Biol. 2003, 84:223-230.
47. Dunlop T.W., Vaisanen S., Frank C., Molnar F., Sinkkonen L., Carlberg C. The human peroxisome proliferator-activated receptor delta gene is a primary target of 1alpha,25-dihydroxyvitamin D3 and its nuclear receptor. J. Mol. Biol. 2005, 349:248-260.
48. Ojuka E.O. Role of calcium and AMP kinase in the regulation of mitochondrial biogenesis and GLUT4 levels in muscle. Proc. Nutr. Soc. 2004, 63:275-278.
49. Wright D.C., Hucker K.A., Holloszy J.O., Han D.H. Ca2+ and AMPK both mediate stimulation of glucose transport by muscle contractions. Diabetes 2004, 53:330-335.
50. Draznin B., Sussman K., Kao M., Lewis D., Sherman N. The existence of an optimal range of cytosolic free calcium for insulin-stimulated glucose transport in rat adipocytes. J. Biol. Chem. 1987, 262:14385-14388.
51. Byyny R.L., LoVerde M., Lloyd S., Mitchell W., Draznin B. Cytosolic calcium and insulin resistance in elderly patients with essential hypertension. Am. J. Hypertens. 1992, 5:459-464.
52. Draznin B., Lewis D., Houlder N., Sherman N., Adamo M., Garvey W.T., et al. Mechanism of insulin resistance induced by sustained levels of cytosolic free calcium in rat adipocytes. Endocrinology 1989, 125:2341-2349.
53. Draznin B., Sussman K.E., Eckel R.H., Kao M., Yost T., Sherman N.A. Possible role of cytosolic free calcium concentrations in mediating insulin resistance of obesity and hyperinsulinemia. J. Clin. Invest. 1988, 82:1848-1852.
54. Draznin B., Sussman K.E., Kao M., Sherman N. Relationship between cytosolic free calcium concentration and 2-deoxyglucose uptake in adipocytes isolated from 2- and 12-month-old rats. Endocrinology 1988, 122:2578-2583.
55. Ohno Y., Suzuki H., Yamakawa H., Nakamura M., Otsuka K., Saruta T. Impaired insulin sensitivity in young, lean normotensive offspring of essential hypertensives: possible role of disturbed calcium metabolism. J. Hypertens. 1993, 11:421-426.
56. Segal S., Lloyd S., Sherman N., Sussman K., Draznin B. Postprandial changes in cytosolic free calcium and glucose uptake in adipocytes in obesity and non-insulin-dependent diabetes mellitus. Horm. Res. 1990, 34:39-44.
57. Zemel M.B. Nutritional and endocrine modulation of intracellular calcium: implications in obesity, insulin resistance and hypertension. Mol. Cell Biochem. 1998, 188:129-136.
58. Williams P.F., Caterson I.D., Cooney G.J., Zilkens R.R., Turtle J.R. High affinity insulin binding and insulin receptor-effector coupling: modulation by Ca2+. Cell Calcium 1990, 11:547-556.
59. Reusch J.E., Begum N., Sussman K.E., Draznin B. Regulation of GLUT-4 phosphorylation by intracellular calcium in adipocytes. Endocrinology 1991, 129:3269-3273.
60. Chiu K.C., Chuang L.M., Lee N.P., Ryu J.M., McGullam J.L., Tsai G.P., et al. Insulin sensitivity is inversely correlated with plasma intact parathyroid hormone level. Metabolism 2000, 49:1501-1505.
61. Reis J.P., von Muhlen D., Kritz-Silverstein D., Wingard D.L., Barrett-Connor E. Vitamin D, parathyroid hormone levels, and the prevalence of metabolic syndrome in community-dwelling older adults. Diabetes Care 2007, 30:1549-1555.
62. Gilsanz V., Kremer A., Mo A.O., Wren T.A., Kremer R. Vitamin D status and its relation to muscle mass and muscle fat in young women. J. Clin. Endocrinol. Metab. 2010, 95:1595-1601.
63. Liu E., Meigs J.B., Pittas A.G., McKeown N.M., Economos C.D., Booth S.L., et al. Plasma 25-hydroxyvitamin D is associated with markers of the insulin resistant phenotype in nondiabetic adults. J. Nutr. 2009, 139:329-334.
64. Scragg R., Sowers M., Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 2004, 27:2813-2818.
65. Chonchol M., Scragg R. 25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey. Kidney Int. 2007, 71:134-139.
66. Forouhi N.G., Luan J., Cooper A., Boucher B.J., Wareham N.J. Baseline serum 25-hydroxy vitamin D is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990-2000. Diabetes 2008, 57:2619-2625.
67. Pinelli N.R., Jaber L.A., Brown M.B., Herman W.H. Serum 25-hydroxy vitamin D and insulin resistance, metabolic syndrome, and glucose intolerance among Arab Americans. Diabetes Care 2010, 33:1373-1375.
68. Zhao G., Ford E.S., Li C. Associations of serum concentrations of 25-hydroxyvitamin D and parathyroid hormone with surrogate markers of insulin resistance among U.S. adults without physician-diagnosed diabetes: NHANES, 2003-2006. Diabetes Care 2010, 33:344-347.
69. Lu L., Yu Z., Pan A., Hu F.B., Franco O.H., Li H., et al. Plasma 25-hydroxyvitamin D concentration and metabolic syndrome among middle-aged and elderly Chinese individuals. Diabetes Care 2009, 32:1278-1283.
70. Gannage-Yared M.H., Chedid R., Khalife S., Azzi E., Zoghbi F., Halaby G. Vitamin D in relation to metabolic risk factors, insulin sensitivity and adiponectin in a young Middle-Eastern population. Eur. J. Endocrinol. 2009, 160:965-971.
71. Clifton-Bligh R.J., McElduff P., McElduff A. Maternal vitamin D deficiency, ethnicity and gestational diabetes. Diabet. Med. 2008, 25:678-684.
72. Duncan B.B., Schmidt M.I., Pankow J.S., Ballantyne C.M., Couper D., Vigo A., et al. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2003, 52:1799-1805.
73. Pittas A.G., Joseph N.A., Greenberg A.S. Adipocytokines and insulin resistance. J. Clin. Endocrinol. Metab. 2004, 89:447-452.
74. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327-334.
75. Riachy R., Vandewalle B., Kerr Conte J., Moerman E., Sacchetti P., Lukowiak B., et al. 1,25-Dihydroxyvitamin D3 protects RINm5F and human islet cells against cytokine-induced apoptosis: implication of the antiapoptotic protein A20. Endocrinology 2002, 143:4809-4819.
76. van Etten E., Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J. Steroid Biochem. Mol. Biol. 2005, 97:93-101.
77. Giulietti A., van Etten E., Overbergh L., Stoffels K., Bouillon R., Mathieu C. Monocytes from type 2 diabetic patients have a pro-inflammatory profile. 1,25-Dihydroxyvitamin D(3) works as anti-inflammatory. Diabetes Res. Clin. Pract. 2007, 77:47-57.
78. Cohen-Lahav M., Douvdevani A., Chaimovitz C., Shany S. The anti-inflammatory activity of 1,25-dihydroxyvitamin D3 in macrophages. J. Steroid Biochem. Mol. Biol. 2007, 103:558-562.
79. Riachy R., Vandewalle B., Moerman E., Belaich S., Lukowiak B., Gmyr V., et al. 1,25-Dihydroxyvitamin D3 protects human pancreatic islets against cytokine-induced apoptosis via down-regulation of the Fas receptor. Apoptosis 2006, 11:151-159.
80. Oh J., Weng S., Felton S.K., Bhandare S., Riek A., Butler B., et al. 1,25(OH)2 vitamin D inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus. Circulation 2009, 120:687-698.
81. Dobnig H., Pilz S., Scharnagl H., Renner W., Seelhorst U., Wellnitz B., et al. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch. Intern. Med. 2008, 168:1340-1349.
82. Nimitphong H., Chanprasertyothin S., Jongjaroenprasert W., Ongphiphadhanakul B. The association between vitamin D status and circulating adiponectin independent of adiposity in subjects with abnormal glucose tolerance. Endocrine 2009, 36:205-210.
83. Shea M.K., Booth S.L., Massaro J.M., Jacques P.F., D'Agostino R.B., Dawson-Hughes B., et al. Vitamin K and vitamin D status: associations with inflammatory markers in the Framingham Offspring Study. Am. J. Epidemiol. 2008, 167:313-320.
84. Luo C., Wong J., Brown M., Hooper M., Molyneaux L., Yue D.K. Hypovitaminosis D in Chinese type 2 diabetes: lack of impact on clinical metabolic status and biomarkers of cellular inflammation. Diab. Vasc. Dis. Res. 2009, 6:194-199.
85. Michos E.D., Streeten E.A., Ryan K.A., Rampersaud E., Peyser P.A., Bielak L.F., et al. Serum 25-hydroxyvitamin D levels are not associated with subclinical vascular disease or C-reactive protein in the old order Amish. Calcif. Tissue Int. 2009, 84:195-202.
86. Sowers J.R. Insulin resistance and hypertension. Am. J. Physiol. Heart Circ. Physiol. 2004, 286:H1597-1602.
87. Wei Y., Sowers J.R., Clark S.E., Li W., Ferrario C.M., Stump C.S. Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase. Am. J. Physiol. Endocrinol. Metab. 2008, 294:E345-351.
88. Li Y.C., Kong J., Wei M., Chen Z.F., Liu S.Q., Cao L.P. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J. Clin. Invest. 2002, 110:229-238.
89. Yuan W., Pan W., Kong J., Zheng W., Szeto F.L., Wong K.E., et al. 1,25-Dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J. Biol. Chem. 2007, 282:29821-29830.
90. Kong J., Li Y.C. Effect of ANG II type I receptor antagonist and ACE inhibitor on vitamin D receptor-null mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003, 285:R255-261.
91. Carthy E.P., Yamashita W., Hsu A., Ooi B.S. 1,25-Dihydroxyvitamin D3 and rat vascular smooth muscle cell growth. Hypertension 1989, 13:954-959.
92. Merke J., Milde P., Lewicka S., Hugel U., Klaus G., Mangelsdorf D.J., et al. Identification and regulation of 1,25-dihydroxyvitamin D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3. Studies in cultured bovine aortic endothelial cells and human dermal capillaries. J. Clin. Invest. 1989, 83:1903-1915.
93. Somjen D., Weisman Y., Kohen F., Gayer B., Limor R., Sharon O., et al. 25-Hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 2005, 111:1666-1671.
94. Borges A.C., Feres T., Vianna L.M., Paiva T.B. Effect of cholecalciferol treatment on the relaxant responses of spontaneously hypertensive rat arteries to acetylcholine. Hypertension 1999, 34:897-901.
95. Borges A.C., Feres T., Vianna L.M., Paiva T.B. Recovery of impaired K+ channels in mesenteric arteries from spontaneously hypertensive rats by prolonged treatment with cholecalciferol. Br. J. Pharmacol. 1999, 127:772-778.
96. Bohr D.F. Vascular smooth muscle: dual effect of calcium. Science 1963, 139:597-599.
97. Behall K.M., Scholfield D.J., Hallfrisch J.G., Kelsay J.L., Reiser S. Seasonal variation in plasma glucose and hormone levels in adult men and women. Am. J. Clin. Nutr. 1984, 40:1352-1356.
98. Campbell I.T., Jarrett R.J., Keen H. Diurnal and seasonal variation in oral glucose tolerance: studies in the Antarctic. Diabetologia 1975, 11:139-145.
99. Nystrom L., Dahlquist G., Ostman J., Wall S., Arnqvist H., Blohme G., et al. Risk of developing insulin-dependent diabetes mellitus (IDDM) before 35 years of age: indications of climatological determinants for age at onset. Int. J. Epidemiol. 1992, 21:352-358.
100. Li X.H., Li T.L., Yang Z., Liu Z.Y., Wei Y.D., Jin S.X., et al. A nine-year prospective study on the incidence of childhood type 1 diabetes mellitus in China. Biomed. Environ. Sci. 2000, 13:263-270.
101. Mohr S.B., Garland C.F., Gorham E.D., Garland F.C. The association between ultraviolet B irradiance, vitamin D status and incidence rates of type 1 diabetes in 51 regions worldwide. Diabetologia 2008, 51:1391-1398.
102. Heath H., Lambert P.W., Service F.J., Arnaud S.B. Calcium homeostasis in diabetes mellitus. J. Clin. Endocrinol. Metab. 1979, 49:462-466.
103. Aksoy H., Akcay F., Kurtul N., Baykal O., Avci B. Serum 1,25 dihydroxy vitamin D (1,25(OH)2D3), 25 hydroxy vitamin D (25(OH)D) and parathormone levels in diabetic retinopathy. Clin. Biochem. 2000, 33:47-51.
104. Boucher B.J., Mannan N., Noonan K., Hales C.N., Evans S.J. Glucose intolerance and impairment of insulin secretion in relation to vitamin D deficiency in east London Asians. Diabetologia 1995, 38:1239-1245.
105. Christiansen C., Christensen M.S., McNair P., Nielsen B., Madsbad S. Vitamin D metabolites in diabetic patients: decreased serum concentration of 24,25-dihydroxyvitamin D. Scand. J. Clin. Lab. Invest. 1982, 42:487-491.
106. Cigolini M., Iagulli M.P., Miconi V., Galiotto M., Lombardi S., Targher G. Serum 25-hydroxyvitamin D3 concentrations and prevalence of cardiovascular disease among type 2 diabetic patients. Diabetes Care 2006, 29:722-724.
107. Hypponen E., Power C. Vitamin D status and glucose homeostasis in the 1958 British birth cohort: the role of obesity. Diabetes Care 2006, 29:2244-2246.
108. Isaia G., Giorgino R., Adami S. High prevalence of hypovitaminosis D in female type 2 diabetic population. Diabetes Care 2001, 24:1496.
109. Nyomba B.L., Bouillon R., Bidingija M., Kandjingu K., De Moor P. Vitamin D metabolites and their binding protein in adult diabetic patients. Diabetes 1986, 35:911-915.
110. Pietschmann P., Schernthaner G., Woloszczuk W. Serum osteocalcin levels in diabetes mellitus: analysis of the type of diabetes and microvascular complications. Diabetologia 1988, 31:892-895.
111. Scragg R., Holdaway I., Singh V., Metcalf P., Baker J., Dryson E. Serum 25-hydroxyvitamin D3 levels decreased in impaired glucose tolerance and diabetes mellitus. Diabetes Res. Clin. Pract. 1995, 27:181-188.
112. Stepan J., Wilczek H., Justova V., Havranek T., Skrha F., Wildtova Z., et al. Plasma 25-hydroxycholecalciferol in oral sulfonylurea treated diabetes mellitus. Horm. Metab. Res. 1982, 14:98-100.
113. Yoho R.M., Frerichs J., Dodson N.B., Greenhagen R., Geletta S. A comparison of vitamin D levels in nondiabetic and diabetic patient populations. J. Am. Podiatr. Med. Assoc. 2009, 99:35-41.
114. Ishida H., Seino Y., Matsukura S., Ikeda M., Yawata M., Yamashita G., et al. Diabetic osteopenia and circulating levels of vitamin D metabolites in type 2 (noninsulin-dependent) diabetes. Metabolism 1985, 34:797-801.
115. Grundy S.M., Brewer H.B., Cleeman J.I., Smith S.C., Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433-438.
116. Baynes K.C., Boucher B.J., Feskens E.J., Kromhout D. Vitamin D, glucose tolerance and insulinaemia in elderly men. Diabetologia 1997, 40:344-347.
117. Ford E.S., Ajani U.A., McGuire L.C., Liu S. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Diabetes Care 2005, 28:1228-1230.
118. Martins D., Wolf M., Pan D., Zadshir A., Tareen N., Thadhani R., et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch. Intern. Med. 2007, 167:1159-1165.
119. Need A.G., O'Loughlin P.D., Horowitz M., Nordin B.E. Relationship between fasting serum glucose, age, body mass index and serum 25 hydroxyvitamin D in postmenopausal women. Clin. Endocrinol. (Oxf.) 2005, 62:738-741.
120. Kositsawat J., Freeman V.L., Gerber B.S., Geraci S. Association of A1c Levels with vitamin D status in U.S. adults: data from the National Health and Nutrition Examination Survey. Diabetes Care 2010, 33:1236-1238.
121. Reis J.P., von Muhlen D., Miller E.R., Michos E.D., Appel L.J. Vitamin D status and cardiometabolic risk factors in the United States adolescent population. Pediatrics 2009, 124:e371-379.
122. Botella-Carretero J.I., Alvarez-Blasco F., Villafruela J.J., Balsa J.A., Vazquez C., Escobar-Morreale H.F. Vitamin D deficiency is associated with the metabolic syndrome in morbid obesity. Clin. Nutr. 2007, 26:573-580.
123. Hypponen E., Boucher B.J., Berry D.J., Power C. 25-Hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: a cross-sectional study in the 1958 British Birth Cohort. Diabetes 2008, 57:298-305.
124. Liu S., Song Y., Ford E.S., Manson J.E., Buring J.E., Ridker P.M. Dietary calcium, vitamin D, and the prevalence of metabolic syndrome in middle-aged and older U.S. women. Diabetes Care 2005, 28:2926-2932.
125. McGill A.T., Stewart J.M., Lithander F.E., Strik C.M., Poppitt S.D. Relationships of low serum vitamin D3 with anthropometry and markers of the metabolic syndrome and diabetes in overweight and obesity. Nutr. J. 2008, 7:4.
126. Orwoll E., Riddle M., Prince M. Effects of vitamin D on insulin and glucagon secretion in non-insulin-dependent diabetes mellitus. Am. J. Clin. Nutr. 1994, 59:1083-1087.
127. Reis J.P., von Muhlen D., Miller E.R. Relation of 25-hydroxyvitamin D and parathyroid hormone levels with metabolic syndrome among US adults. Eur. J. Endocrinol. 2008, 159:41-48.
128. Snijder M., van Dam R., Visser M., Deeg D., Seidell J., Lips P. To: C. Mathieu, C. Gysemans, A. Giulietti, R. Bouillon, Vitamin D and diabetes. Diabetologia 2006, 49:217-218.
129. Wareham N.J., Byrne C.D., Carr C., Day N.E., Boucher B.J., Hales C.N. Glucose intolerance is associated with altered calcium homeostasis: a possible link between increased serum calcium concentration and cardiovascular disease mortality. Metabolism 1997, 46:1171-1177.
130. Bell N.H., Greene A., Epstein S., Oexmann M.J., Shaw S., Shary J. Evidence for alteration of the vitamin D-endocrine system in blacks. J. Clin. Invest. 1985, 76:470-473.
131. Hjelmesaeth J., Hofso D., Aasheim E.T., Jenssen T., Moan J., Hager H., et al. Parathyroid hormone, but not vitamin D, is associated with the metabolic syndrome in morbidly obese women and men: a cross-sectional study. Cardiovasc. Diabetol. 2009, 8:7.
132. Parikh S.J., Edelman M., Uwaifo G.I., Freedman R.J., Semega-Janneh M., Reynolds J., et al. The relationship between obesity and serum 1,25-dihydroxy vitamin D concentrations in healthy adults. J. Clin. Endocrinol. Metab. 2004, 89:1196-1199.
133. Wortsman J., Matsuoka L.Y., Chen T.C., Lu Z., Holick M.F. Decreased bioavailability of vitamin D in obesity. Am. J. Clin. Nutr. 2000, 72:690-693.
134. Jorde R., Sneve M., Emaus N., Figenschau Y., Grimnes G. Cross-sectional and longitudinal relation between serum 25-hydroxyvitamin D and body mass index: the Tromso study. Eur. J. Nutr. 2010, 49:401-407.
135. Pittas A.G., Dawson-Hughes B., Li T., Van Dam R.M., Willett W.C., Manson J.E., et al. Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care 2006, 29:650-656.
136. Knekt P., Laaksonen M., Mattila C., Harkanen T., Marniemi J., Heliovaara M., et al. Serum vitamin D and subsequent occurrence of type 2 diabetes. Epidemiology (Cambridge, Mass.) 2008, 19:666-671.
137. Liu E., Meigs J.B., Pittas A.G., Economos C.D., McKeown N.M., Booth S.L., et al. Predicted 25-hydroxyvitamin D score and incident type 2 diabetes in the Framingham Offspring Study. Am. J. Clin. Nutr. 2010, 91:1627-1633.
138. Pittas A.G., Qi S., Manson J.E., Dawson-Hughes B., Hu F.B. Plasma 25-hydroxyvitamin D concentration and risk of incident type 2 diabetes in women. Diabetes Care 2010, in press.
139. Nilas L., Christiansen C. Treatment with vitamin D or its analogues does not change body weight or blood glucose level in postmenopausal women. Int. J. Obes. 1984, 8:407-411.
140. Pittas A.G., Harris S.S., Stark P.C., Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care 2007, 30:980-986.
141. Hsia J., Heiss G., Ren H., Allison M., Dolan N.C., Greenland P., et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007, 115:846-854.
142. de Boer I.H., Tinker L.F., Connelly S., Curb J.D., Howard B.V., Kestenbaum B., et al. Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women's Health Initiative. Diabetes Care 2008, 31:701-707.
143. Sugden J.A., Davies J.I., Witham M.D., Morris A.D., Struthers A.D. Vitamin D improves endothelial function in patients with type 2 diabetes mellitus and low vitamin D levels. Diabet. Med. 2008, 25:320-325.
144. Avenell A., Cook J.A., MacLennan G.S., McPherson G.C. Vitamin D supplementation and type 2 diabetes: a substudy of a randomised placebo-controlled trial in older people (RECORD trial, ISRCTN 51647438). Age Ageing 2009, 38:606-609.
145. Zittermann A., Frisch S., Berthold H.K., Gotting C., Kuhn J., Kleesiek K., et al. Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am. J. Clin. Nutr. 2009, 89:1321-1327.
146. von Hurst P.R., Stonehouse W., Coad J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient - a randomised, placebo-controlled trial. Br. J. Nutr. 2010, 103:549-555.
147. Jorde R., Sneve M., Torjesen P., Figenschau Y. No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year. J. Intern. Med. 2010, 267:462-472.
148. Witham M.D., Dove F.J., Dryburgh M., Sugden J.A., Morris A.D., Struthers A.D. The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial. Diabetologia 2010, 53:2112-2119.
149. Jorde R., Sneve M., Torjesen P.A., Figenschau Y., Goransson L.G., Omdal R. No effect of supplementation with cholecalciferol on cytokines and markers of inflammation in overweight and obese subjects. Cytokine 2010, 50:175-180.
150. Jorde R., Figenschau Y. Supplementation with cholecalciferol does not improve glycaemic control in diabetic subjects with normal serum 25-hydroxyvitamin D levels. Eur. J. Nutr. 2009, 48:349-354.
151. Nagpal J., Pande J.N., Bhartia A. A double-blind, randomized, placebo-controlled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. Diabet. Med. 2009, 26:19-27.
152. Sanders K.M., Stuart A.L., Williamson E.J., Simpson J.A., Kotowicz M.A., Young D., et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 2010, 303:1815-1822.
153. Dawson-Hughes B., Harris S.S. High-dose vitamin D supplementation: too much of a good thing?. JAMA 2010, 303:1861-1862.
154. Lappe J.M., Travers-Gustafson D., Davies K.M., Recker R.R., Heaney R.P. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am. J. Clin. Nutr. 2007, 85:1586-1591.
155. Brennan P.J., Greenberg G., Miall W.E., Thompson S.G. Seasonal variation in arterial blood pressure. J. Br. Med. (Clin. Res. Ed.) 1982, 285:919-923.
156. Kunes J., Tremblay J., Bellavance F., Hamet P. Influence of environmental temperature on the blood pressure of hypertensive patients in Montreal. Am. J. Hypertens. 1991, 4:422-426.
157. Woodhouse P.R., Khaw K.T., Plummer M. Seasonal variation of blood pressure and its relationship to ambient temperature in an elderly population. J. Hypertens. 1993, 11:1267-1274.
158. Minami J., Kawano Y., Ishimitsu T., Yoshimi H., Takishita S. Seasonal variations in office, home and 24h ambulatory blood pressure in patients with essential hypertension. J. Hypertens. 1996, 14:1421-1425.
159. Narang R., Wasir H.S. Seasonal variation in the incidence of hypertension and coronary artery disease. Int. J. Cardiol. 1996, 56:90-92.
160. He J., Klag M.J., Wu Z., Whelton P.K. Stroke in the People's Republic of China. I. Geographic variations in incidence and risk factors. Stroke 1995, 26:2222-2227.
161. Rostand S.G. Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension 1997, 30:150-156.
162. Krause R., Buhring M., Hopfenmuller W., Holick M.F., Sharma A.M. Ultraviolet B and blood pressure. Lancet 1998, 352:709-710.
163. Lind L., Hanni A., Lithell H., Hvarfner A., Sorensen O.H., Ljunghall S. Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. Am. J. Hypertens. 1995, 8:894-901.
164. Sowers M.R., Wallace R.B., Lemke J.H. The association of intakes of vitamin D and calcium with blood pressure among women. Am. J. Clin. Nutr. 1985, 42:135-142.
165. Joffres M.R., Reed D.M., Yano K. Relationship of magnesium intake and other dietary factors to blood pressure: the Honolulu heart study. Am. J. Clin. Nutr. 1987, 45:469-475.
166. Scragg R., Sowers M., Bell C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am. J. Hypertens. 2007, 20:713-719.
167. Judd S.E., Nanes M.S., Ziegler T.R., Wilson P.W., Tangpricha V. Optimal vitamin D status attenuates the age-associated increase in systolic blood pressure in white Americans: results from the third National Health and Nutrition Examination Survey. Am. J. Clin. Nutr. 2008, 87:136-141.
168. Jorde R., Figenschau Y., Emaus N., Hutchinson M., Grimnes G. Serum 25-hydroxyvitamin D levels are strongly related to systolic blood pressure but do not predict future hypertension. Hypertension 2010, 55:792-798.
169. Snijder M.B., Lips P., Seidell J.C., Visser M., Deeg D.J., Dekker J.M., et al. Vitamin D status and parathyroid hormone levels in relation to blood pressure: a population-based study in older men and women. J. Intern. Med. 2007, 261:558-565.
170. Schmitz K.J., Skinner H.G., Bautista L.E., Fingerlin T.E., Langefeld C.D., Hicks P.J., et al. Association of 25-hydroxyvitamin D with blood pressure in predominantly 25-hydroxyvitamin D deficient Hispanic and African Americans. Am. J. Hypertens. 2009, 22:867-870.
171. Forman J.P., Bischoff-Ferrari H.A., Willett W.C., Stampfer M.J., Curhan G.C. Vitamin D intake and risk of incident hypertension: results from three large prospective cohort studies. Hypertension 2005, 46:676-682.
172. Forman J.P., Curhan G.C., Taylor E.N. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. Hypertension 2008, 52:828-832.
173. Forman J.P., Giovannucci E., Holmes M.D., Bischoff-Ferrari H.A., Tworoger S.S., Willett W.C., et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007, 49:1063-1069.
174. Wang L., Manson J.E., Buring J.E., Lee I.M., Sesso H.D. Dietary intake of dairy products, calcium, and vitamin D and the risk of hypertension in middle-aged and older women. Hypertension 2008, 51:1073-1079.
175. Scragg R., Khaw K.T., Murphy S. Effect of winter oral vitamin D3 supplementation on cardiovascular risk factors in elderly adults. Eur. J. Clin. Nutr. 1995, 49:640-646.
176. Pfeifer M., Begerow B., Minne H.W., Nachtigall D., Hansen C. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J. Clin. Endocrinol. Metab. 2001, 86:1633-1637.
177. Schleithoff S.S., Zittermann A., Tenderich G., Berthold H.K., Stehle P., Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am. J. Clin. Nutr. 2006, 83:754-759.
178. Major G.C., Alarie F., Dore J., Phouttama S., Tremblay A. Supplementation with calcium + vitamin D enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations. Am. J. Clin. Nutr. 2007, 85:54-59.
179. Margolis K.L., Ray R.M., Van Horn L., Manson J.E., Allison M.A., Black H.R., et al. Effect of calcium and vitamin D supplementation on blood pressure: the Women's Health Initiative Randomized Trial. Hypertension 2008, 52:847-855.
180. Giovannucci E., Liu Y., Hollis B.W., Rimm E.B. 25-Hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch. Intern. Med. 2008, 168:1174-1180.
181. Jacobs D.R., Steffen L.M. Nutrients, foods, and dietary patterns as exposures in research: a framework for food synergy. Am. J. Clin. Nutr. 2003, 78:508S-513S.
182. Grundberg E., Brandstrom H., Ribom E.L., Ljunggren O., Mallmin H., Kindmark A. Genetic variation in the human vitamin D receptor is associated with muscle strength, fat mass and body weight in Swedish women. Eur. J. Endocrinol. 2004, 150:323-328.
183. Smolders J., Peelen E., Thewissen M., Menheere P., Cohen Tervaert J.W., Hupperts R., et al. The relevance of vitamin D receptor gene polymorphisms for vitamin D research in multiple sclerosis. Autoimmun. Rev. 2009, 8:621-626.
184. Wang T.J., Zhang F., Richards J.B., Kestenbaum B., van Meurs J.B., Berry D., et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 2010, 376:180-188.
185. Nesby-O'Dell S., Scanlon K.S., Cogswell M.E., Gillespie C., Hollis B.W., Looker A.C., et al. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988-1994. Am. J. Clin. Nutr. 2002, 76:187-192.
186. Aloia J.F. African Americans, 25-hydroxyvitamin D, and osteoporosis: a paradox. Am. J. Clin. Nutr. 2008, 88:545S-550S.
187. Institute of Medicine Dietary reference intakes for calcium and vitamin D 2011, The National Academies Press, Washington, DC.
188. Bischoff-Ferrari H.A., Giovannucci E., Willett W.C., Dietrich T., Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am. J. Clin. Nutr. 2006, 84:18-28.
189. Hollis B.W. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J. Nutr. 2005, 135:317-322.
190. Talwar S.A., Aloia J.F., Pollack S., Yeh J.K. Dose response to vitamin D supplementation among postmenopausal African American women. Am. J. Clin. Nutr. 2007, 86:1657-1662.